Pakistan
COVID-19 treatment: Pakistan likely to be first to complete ‘immunoglobulin therapy research’
- The therapy uses immunoglobulin (IG), which is rich in the antibodies that target the virus.
- In June, DUHS started trial of the therapy on 30 participants, most from the high-risk group of people above the age of 60, with many suffering from diabetes, hypertension and other comorbidities.











































































































































































































































































